Inotek shares crater (again) as another glaucoma drug study flops
For the second time this year Inotek Pharmaceuticals says its lead drug failed a clinical study for glaucoma. And the successive flop once again hammered …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.